Lentiviral Hematopoietic Stem Cell Gene Therapy in Inherited Metabolic Disorders
- 1 October 2014
- journal article
- review article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 25 (10) , 862-865
Abstract
After more than 20 years of development, lentiviral hematopoietic stem cell gene therapy has entered the stage of initial clinical implementation for immune deficiencies and storage disorders. This brief review summarizes the development and applications, focusing on the lysosomal enzyme deficiencies, especially Pompe disease.Keywords
This publication has 35 references indexed in Scilit:
- Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene TherapyMolecular Therapy, 2011
- Autologous Transplantation of Lentivector/Acid Ceramidase–Transduced Hematopoietic Cells in Nonhuman PrimatesHuman Gene Therapy, 2011
- Integration profile of retroviral vector in gene therapy treated patients is cell‐specific according to gene expression and chromatin conformation of target cellEMBO Molecular Medicine, 2011
- Efficacy of Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2010
- Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cellsBlood, 2007
- Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapyJournal of Clinical Investigation, 2007
- Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoJournal of Clinical Investigation, 2007
- Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapyJournal of Clinical Investigation, 2007
- Effective cell and gene therapy in a murine model of Gaucher diseaseProceedings of the National Academy of Sciences, 2006
- Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapyProceedings of the National Academy of Sciences, 2006